FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387208274> ?p ?o ?g. }

• W4387208274 endingPage "e21" @default.
• W4387208274 startingPage "e21" @default.
• W4387208274 abstract "Consolidation immunotherapy after chemoradiotherapy (CRT) is the standard of care for unresectable stage III non-small cell lung cancer (NSCLC). However, whether upfront immunotherapy before CRT has similar benefits has not been addressed. This study aimed at exploring the efficacy and safety of induction immunotherapy for unresectable stage III NSCLC through real-world data.Patients diagnosed with stage III NSCLC who received immunotherapy in combination with sequential (sCRT) or concurrent CRT (cCRT) between November 2018 and December 2021 were retrospectively identified. Patients were divided into induction (Ind), consolidation (Con) and induction plus consolidation (Ind+Con) immunotherapy groups. Progression-free survival (PFS) and overall survival (OS) were assessed from the initiation of treatment and estimated by Kaplan‒Meier method. The potential factors affecting PFS and OS were analyzed by univariate and multivariate Cox regression models.One hundred and two patients were included, with 52 (51.0%) patients in the Ind group, 35 (34.3%) in the Con group and 15 (14.7%) in the Ind+Con group. Median PFS was 24.0 months vs. 36.0 months vs. 19.0 months in the three groups, and 2-year PFS were 43.0% vs 51.1% vs 44.4% (p = 0.940). Median OS was not reached (NR) vs. 44.0 months vs. NR, with a 2-year OS rate of 80.5% vs. 84.4% vs. 86.2% (p = 0.861). In the cCRT setting, 2-year PFS rates were 56.7% vs. 71.6% vs. 100.0% (p = 0.439), 2-year OS rates were 92.3% vs. 89.3% vs. 100.0% in the three groups (p = 0.827). In multivariate analysis, elder (HR = 0.487, p = 0.037) and cCRT (HR = 0.282, p = 0.001) were the independent factors favoring PFS, while only elder (HR = 0.088, p = 0.021) was the independent factors favoring OS. Adverse events were similar in the three arms. Further analysis found the objective response rate (ORR) and disease control rate (DCR) in the Ind and Ind+Con group after induction immunotherapy were 59.7% and 98.5%, respectively. Only 1 (1.5%) patient developed progression. Subgroup analysis showed no significant difference in PFS (p = 0.520) and OS (p = 0.116) between patients who responded to induction immunotherapy (PR+CR) and those who did not (SD+PD). Patients with <4 cycles of induction immunotherapy exhibited numerically better PFS than those with ≥4 cycles of induction immunotherapy (p = 0.113) and improved OS (p = 0.021).Induction immunotherapy may achieve similar survival benefits to consolidation immunotherapy, and the combination of induction and consolidation immunotherapy with cCRT appears to achieve better outcomes. It seems feasible and safe to upfront immunotherapy before CRT, and further investigations on the combination of induction immunotherapy and CRT are warranted." @default.
• W4387208274 created "2023-09-30" @default.
• W4387208274 creator A5012845876 @default.
• W4387208274 creator A5025495733 @default.
• W4387208274 creator A5027168462 @default.
• W4387208274 creator A5030967805 @default.
• W4387208274 creator A5037677450 @default.
• W4387208274 creator A5043273438 @default.
• W4387208274 creator A5048678875 @default.
• W4387208274 date "2023-10-01" @default.
• W4387208274 modified "2023-10-17" @default.
• W4387208274 title "Induction Immunotherapy vs. Consolidation Immunotherapy for Unresectable Stage III NSCLC" @default.
• W4387208274 doi "https://doi.org/10.1016/j.ijrobp.2023.06.694" @default.
• W4387208274 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784874" @default.
• W4387208274 hasPublicationYear "2023" @default.
• W4387208274 type Work @default.
• W4387208274 citedByCount "0" @default.
• W4387208274 crossrefType "journal-article" @default.
• W4387208274 hasAuthorship W4387208274A5012845876 @default.
• W4387208274 hasAuthorship W4387208274A5025495733 @default.
• W4387208274 hasAuthorship W4387208274A5027168462 @default.
• W4387208274 hasAuthorship W4387208274A5030967805 @default.
• W4387208274 hasAuthorship W4387208274A5037677450 @default.
• W4387208274 hasAuthorship W4387208274A5043273438 @default.
• W4387208274 hasAuthorship W4387208274A5048678875 @default.
• W4387208274 hasConcept C121608353 @default.
• W4387208274 hasConcept C126322002 @default.
• W4387208274 hasConcept C143998085 @default.
• W4387208274 hasConcept C144301174 @default.
• W4387208274 hasConcept C146357865 @default.
• W4387208274 hasConcept C151730666 @default.
• W4387208274 hasConcept C2776256026 @default.
• W4387208274 hasConcept C2776694085 @default.
• W4387208274 hasConcept C2777701055 @default.
• W4387208274 hasConcept C2778424827 @default.
• W4387208274 hasConcept C38180746 @default.
• W4387208274 hasConcept C50382708 @default.
• W4387208274 hasConcept C71924100 @default.
• W4387208274 hasConcept C86803240 @default.
• W4387208274 hasConceptScore W4387208274C121608353 @default.
• W4387208274 hasConceptScore W4387208274C126322002 @default.
• W4387208274 hasConceptScore W4387208274C143998085 @default.
• W4387208274 hasConceptScore W4387208274C144301174 @default.
• W4387208274 hasConceptScore W4387208274C146357865 @default.
• W4387208274 hasConceptScore W4387208274C151730666 @default.
• W4387208274 hasConceptScore W4387208274C2776256026 @default.
• W4387208274 hasConceptScore W4387208274C2776694085 @default.
• W4387208274 hasConceptScore W4387208274C2777701055 @default.
• W4387208274 hasConceptScore W4387208274C2778424827 @default.
• W4387208274 hasConceptScore W4387208274C38180746 @default.
• W4387208274 hasConceptScore W4387208274C50382708 @default.
• W4387208274 hasConceptScore W4387208274C71924100 @default.
• W4387208274 hasConceptScore W4387208274C86803240 @default.
• W4387208274 hasIssue "2" @default.
• W4387208274 hasLocation W43872082741 @default.
• W4387208274 hasLocation W43872082742 @default.
• W4387208274 hasOpenAccess W4387208274 @default.
• W4387208274 hasPrimaryLocation W43872082741 @default.
• W4387208274 hasRelatedWork W2361700749 @default.
• W4387208274 hasRelatedWork W2367054191 @default.
• W4387208274 hasRelatedWork W2367617697 @default.
• W4387208274 hasRelatedWork W2386134303 @default.
• W4387208274 hasRelatedWork W2405817813 @default.
• W4387208274 hasRelatedWork W2411442805 @default.
• W4387208274 hasRelatedWork W2415741046 @default.
• W4387208274 hasRelatedWork W2981648456 @default.
• W4387208274 hasRelatedWork W3030061193 @default.
• W4387208274 hasRelatedWork W3032086589 @default.
• W4387208274 hasVolume "117" @default.
• W4387208274 isParatext "false" @default.
• W4387208274 isRetracted "false" @default.
• W4387208274 workType "article" @default.